IL-12 as an adjuvant for Bordetella pertussis vaccines
US6929794B1 · kind B1 · utility
2Cited by
6References
43Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 29, 1998 |
| Grant date | Aug 16, 2005 |
| Priority date | — |
| Expiry date | Oct 29, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55538
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.